Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Central Africa has been steadily developing over the past few years.
Customer preferences: Customers in Central Africa are showing an increasing demand for Anti-Coagulants due to the rise in cardiovascular diseases and other related illnesses. Patients are becoming more aware of the benefits of Anti-Coagulants in preventing blood clots and reducing the risk of stroke, leading to a higher demand for these products.
Trends in the market: One of the major trends in the Anti-Coagulants market in Central Africa is the increasing use of direct oral anticoagulants (DOACs) over traditional anticoagulants such as warfarin. DOACs are more convenient to use, have fewer side effects, and do not require regular blood tests, making them a preferred choice among patients. Additionally, there has been a rise in the number of patients switching from injectable anticoagulants to oral ones, further driving the growth of the market.
Local special circumstances: Central Africa has a high prevalence of cardiovascular diseases, which has contributed to the growth of the Anti-Coagulants market. The region also has a growing geriatric population, who are more susceptible to these diseases. Moreover, the lack of access to healthcare facilities and medical professionals in certain parts of the region has led to an increase in self-medication, resulting in a higher demand for over-the-counter Anti-Coagulants.
Underlying macroeconomic factors: The Anti-Coagulants market in Central Africa is also influenced by macroeconomic factors such as government policies and regulations, healthcare infrastructure, and economic growth. The region has seen an increase in government expenditure on healthcare, which has led to the expansion of healthcare facilities and the availability of better medical equipment. Economic growth has also led to an increase in disposable income, allowing patients to afford better quality healthcare and medication. Furthermore, the increasing number of partnerships and collaborations between pharmaceutical companies and healthcare providers has led to the development of new Anti-Coagulants and increased access to these products.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
